[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343514-105":3,"doc-detail-343514-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","loss-of-heterozygosity-of-cyp2d6-enhances-the-sensitivity-of-hepatocellular-carcinomas-to-talazoparib","Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib","","Loss of heterozygosity (LOH) reduces genetic diversity within cancer genomes, potentially leaving tumor cells dependent on loss-of-function allele–specific protein deficiencies. This study identifies CYP2D6 as a frequently LOH-targeted gene and links its compromised activity to drug response. Using a large variant screening approach and cell and organoid models, the work tests clinical and trial compounds for genotype-dependent cytotoxicity. Talazoparib, and MK-8776, show heightened toxicity in CYP2D6-impaired hepatocellular cancer models, supporting allele-selective collateral lethality.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/loss-of-heterozygosity-of-cyp2d6-enhances-the-sensitivity-of-hepatocellular-carcinomas-to-talazoparib/343514/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/loss-of-heterozygosity-of-cyp2d6-enhances-the-sensitivity-of-hepatocellular-carcinomas-to-talazoparib/343514.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the role of loss of heterozygosity (LOH) in this study?","Question",{"text":63,"@type":64},"LOH reduces allelic diversity in cancer genomes and can leave tumor cells retaining only loss-of-function alleles, creating vulnerabilities that may be exploited therapeutically.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study identify CYP2D6 as a relevant target?",{"text":68,"@type":64},"The authors mined the 1000 Genomes dataset for loss-of-function variants and selected rs3892097 in CYP2D6 because its genomic region frequently undergoes LOH in multiple tumor types, including hepatocellular cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"Which drugs showed increased sensitivity in CYP2D6-compromised models?",{"text":72,"@type":64},"Talazoparib and MK-8776 demonstrated consistently heightened cytotoxic effects against engineered hepatocellular cancer cell models with compromised CYP2D6 activity, and talazoparib showed genotype-dependent effects in primary organoids.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343514,1790176299,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542",8,"Articles   \nLoss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib  \nXiaonan Zhang,a Natallia Rameika,a Lei Zhong,a Verónica Rendo,a Margus Veanes,a Snehangshu Kundu,a Sandro Nuciforo,b Jordan Dupuis,a Muhammad Al Azhar,a Ioanna Tsiara,d Pauline Seeburger,d Shahed Al Nassralla,a Viktor Ljungström,a Richard Svensson,e,f Ivaylo Stoimenov,a Per Artursson,f Markus H. Heim,b,c Daniel Globisch,d and Tobias Sjöbloma,∗  \naDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, SE-751 85, Uppsala, Sweden  \nbDepartment of Biomedicine, University Hospital and University of Basel, CH-4031, Basel, Switzerland cClarunis University Center for Gastrointestinal and Liver Diseases, CH-4002, Basel, Switzerland dDepartment of Chemistry-BMC, Science for Life Laboratory, Uppsala University, SE-751 23, Uppsala, Sweden  \neUppsala Drug Optimization and Pharmaceutical Proﬁling Facility (UDOPP), SciLifeLab Chemical Biology Consortium Sweden (CBCS), Department of Pharmacy, Uppsala University, 751 23, Uppsala, Sweden  \nfDepartment of Pharmacy, Uppsala University, Husargatan 3, 751 23, Uppsala, Sweden  \nSummary  \nBackground Loss of heterozygosity (LOH) diminishes genetic diversity within cancer genomes. A tumour arising inan individual heterozygous for a functional and a loss-of-function (LoF) allele of a gene occasionally retain only the LoF allele. This can result in deﬁciency of speciﬁc protein activities in cancer cells, creating unique differences between tumour cells and normal cells of the individual. Such differences may constitute vulnerabilities that can be exploited through allele-speciﬁc therapies.  \nMethods To discover frequently lost genes with prevalent LoF alleles, we mined the 1000 Genomes dataset for SNVs causing protein truncation through base substitution, indels or splice site disruptions, resulting in 60 LoF variants in 60 genes. From these, the variant rs3892097 in the liver enzyme CYP2D6 was selected because it is located within a genomic region that frequently undergoes LOH in several tumor types including hepatocellular cancers. To evaluate the relationship between CYP2D6 activity and the toxicities of anticancer agents, we screened 525 compounds currently in clinical use or undergoing clinical trials using cell model systems with or without CYP2D6 activity.  \nFindings We identiﬁed 12 compounds, AZD-3463, CYC-116, etoposide, everolimus, GDC-0349, lenvatinib, MK-8776, PHA-680632, talazoparib, tyrphostin 9, VX-702, and WZ-3146, using an engineered HEK293T cell model. Of these, talazoparib and MK-8776 demonstrated consistently heightened cytotoxic effects against cells with compromised CYP2D6 activity in engineered hepatocellular cancer cell models. Moreover, talazoparib displayed CYP2D6 genotype dependent effects on primary hepatocellular carcinoma organoids.  \nInterpretation Exploiting the loss of drug-metabolizing enzyme gene activity in tumor cells following loss of heterozygosity could present a promising therapeutic strategy for targeted cancer treatment.  \nFunding This work was funded by Barncancerfonden (T.S, PR2022-0099 and PR2020-0171, X.Z, TJ2021-0111), Cancerfonden (T.S, 211719Pj and D.G, 222449Pj), Vetenskapsrådet (T.S, 2020-02371 and D.G, 2020-04707), and the Erling Persson Foundation (T.S, 2020-0037 and T.S, 2023-0113) .  \nCopyright © 2024 The Author(s) . Published by Elsevier B.V. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nKeywords: Loss of heterozygosity; Loss of function; Hepatocellular carcinomas; CYP2D6 and talazoparib  \nIntroduction  \nDevelopment of targeted anti-cancer therapy has mainly focused on molecular differences between cancer and normal cells, seeking to identify drug targets enabling selective killing of tumor cells. Such therapies  \nalternatively target gain of function in oncogenes, or loss of function in ","cbCail1BuFvAPvru","https://ap.wps.com/l/cbCail1BuFvAPvru","pdf",1548781,20,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n## Funding\n# Introduction\n# Research in context\n## Evidence before this study\n## Added value of this study\n## Implications of all the available evidence","[{\"question\":\"What is the role of loss of heterozygosity (LOH) in this study?\",\"answer\":\"LOH reduces allelic diversity in cancer genomes and can leave tumor cells retaining only loss-of-function alleles, creating vulnerabilities that may be exploited therapeutically.\"},{\"question\":\"How did the study identify CYP2D6 as a relevant target?\",\"answer\":\"The authors mined the 1000 Genomes dataset for loss-of-function variants and selected rs3892097 in CYP2D6 because its genomic region frequently undergoes LOH in multiple tumor types, including hepatocellular cancers.\"},{\"question\":\"Which drugs showed increased sensitivity in CYP2D6-compromised models?\",\"answer\":\"Talazoparib and MK-8776 demonstrated consistently heightened cytotoxic effects against engineered hepatocellular cancer cell models with compromised CYP2D6 activity, and talazoparib showed genotype-dependent effects in primary organoids.\"}]","Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib | PDF",1790051357,50,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10b2ae000667842cf327a82e53001bd7.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f28ebb99d2dfc1274bffb53468b211c.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bac847aeedea5f48a25821409364a2e.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93a8ab6c71d9a2f6e3aab7943e9e9585.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,135,139,144,147,150,153,157],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":98,"slug":138},6,"Technology","technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":92,"slug":149},"Religion & Spirituality","religion-spirituality",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":151,"show_sort_weight":92,"slug":152},"World Cup","world-cup",{"id":154,"doc_module":4,"doc_module_name":25,"category_name":155,"show_sort_weight":154,"slug":156},10,"Lifestyle","lifestyle",{"id":158,"doc_module":4,"doc_module_name":25,"category_name":159,"show_sort_weight":131,"slug":160},19,"General","general"]